July 24th 2024
Results from an induction trial and maintenance trial show Skyrizi (risankizumab) improved endoscopic and histological secondary outcomes characterized by endoscopic improvement, remission, and histological, endoscopic, and mucosal improvements in patients with moderately to severely active ulcerative colitis.
The Current Status of European Research Related to COVID-19: The EUCROF Perspective
Successful collaborations between Pharma/Biotech/Device industries and CROs will play a key role in an effective fight against the global COVID-19 pandemic.